Search

Your search keyword '"Liu, Geoffrey"' showing total 2,647 results

Search Constraints

Start Over You searched for: Author "Liu, Geoffrey" Remove constraint Author: "Liu, Geoffrey"
2,647 results on '"Liu, Geoffrey"'

Search Results

1. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America.

2. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.

4. Smoking and alcohol by HPV status in head and neck cancer: a Mendelian randomization study

5. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis

6. Impact of individual level uncertainty of lung cancer polygenic risk score (PRS) on risk stratification

7. Smart Speech Segmentation using Acousto-Linguistic Features with look-ahead

9. Assessment of Glomerular Filtration Rate in Patients with Cancer: A Statement from the American Society of Onco-Nephrology

10. Assessment of GFR in Patients with Cancer Part 2: Anticancer Therapies – Perspectives from the ASON

12. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

13. Outcomes with non-small cell lung cancer and brain-only metastasis

16. Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer.

17. Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC

18. Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population

19. Accounting for EGFR mutations in epidemiological analyses of non-small cell lung cancers: Examples based on the International Lung Cancer Consortium data

20. The diversity of inhibitory receptor co-expression patterns of exhausted CD8+ T cells in oropharyngeal carcinoma

22. Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis

25. Behavioral Repertoires for Soft Tensegrity Robots

28. Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer

29. Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies

31. Association between duration of smoking abstinence before non-small-cell lung cancer diagnosis and survival: a retrospective, pooled analysis of cohort studies

32. The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients

33. A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol

35. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study

36. Mosaic Chromosomal Alterations Are Associated With Increased Lung Cancer Risk: Insight From the INTEGRAL-ILCCO Cohort Analysis

37. Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer: a mixed methods study

38. Immune-mediated genetic pathways resulting in pulmonary function impairment increase lung cancer susceptibility.

41. Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium

42. Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence

43. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

44. Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer

47. Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.

48. The impact of admitting ward on resource utilization and outcomes among hospitalized cancer survivors.

49. Comparing the characteristics and outcomes of hospitalizations between cancer and non-cancer survivors.

Catalog

Books, media, physical & digital resources